14th Apr 2015 07:48
LONDON (Alliance News) - GW Pharmaceuticals PLC on Tuesday said its Epidiolex cannaboid product has been highlighted in a new report by the American Academy of Neurology.
GW said safety and efficacy data on the drug will be presented as the academy's annual meeting on April 22, after which GW will make an additional disclosure.
"We are pleased that the American Academy of Neurology has chosen to highlight the importance of the Epidiolex expanded access data and look forward to more detailed information at the forthcoming AAN Annual Meeting being made available by the physicians leading this programme," said Justin Gover, GW's chief executive.
Shares in GW were up 0.8% to 555.05 pence on Tuesday morning.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L